As demand for obesity drugs like Wegovy, Zepbound, Mounjaro and Ozempic, outpaces supply, online scams are rising, according to cybersecurity experts.
Eli Lilly and Novo Nordisk continue to ramp production facilities and capacity for booming weight-loss drugs like Wegovy and Zepbound, with Lilly this week announcing a $3 billion investment to increase obesity drug production at a Wisconsin plant.
Consumers have received Lilly- and Novo-branded GLP-1s from unauthorized sellers, counterfeit versions, completely different medications or nothing at all — other than an expensive rip-off. Most disturbing, Novo told CNBC that as of mid-November, it is aware of 14 deaths and 144 hospitalizations of people who had taken compounded semaglutide, the active pharmaceutical ingredient in Ozempic and Wegovy.
No-delivery ploys can exact a serious financial toll on victims, but "the more scary ones are where you do get a product and don't even know whether you can trust or if it's a valid company," said Abhishek Karnik, director for threat research and response for cybersecurity firm McAfee.across malicious websites, scam emails and texts, posts on social media and online marketplace listings.
"The social media platforms are the new street corners for drug dealers, and they move from place to place," Galvin said. "It's a game of whack-a-mole."
Obesity Weight Management Social Media Health Care Industry Pharmaceuticals Crime Meta Platforms Inc Hims & Hers Health Inc Novo Nordisk A/S Novo Nordisk A/S LILLY DRN Cybersecurity Technology Suppress Zephr Business News
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, ZepboundEli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products.
Read more »
Zepbound Bests Wegovy for Weight Loss in New TrialZepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Read more »
Zepbound results in more weight loss than Wegovy in trial, Eli Lilly saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
Zepbound leads to more weight loss than Wegovy, study findsStudy participants treated with Zepbound lost 20% of their body weight.
Read more »